Core Viewpoint - Company Haohai Biological Technology (688366.SH) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.3515 million, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Overview - Jiangxi Ruiji was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction [1] - The acquisition allows the company to gain distribution rights for Ruiji's products in China, entering the high-value medical device sector of biological amniotic membranes [1] Group 3: Strategic Implications - The acquisition is expected to effectively supplement the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1] - Ruiji's amniotic membrane materials possess human-derived biological characteristics, providing essential technical and material foundations for the company's research and development in regenerative medicine and tissue engineering [1] - This move is anticipated to drive subsequent product innovation and technological upgrades for the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海市錦天城律師事務所關於上海 昊海生物科技股份有限公司2021年A股限制性股票激勵計劃作廢部分已授予但尚 未歸屬的限制性股票相關事項之法律意見書》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年12月12日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於作廢2021年A股限制性股票激勵計劃部份已授予但尚未歸屬的限制性股票的公 告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年12月12日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 ...

本文作者可以追加内容哦 ! 黎映彤，彼具备上市规则第3.28条所规定的专业资格，已获委任为联席公司秘书、授权代表及法律程序 代理人，自2025年12月12日起生效。田敏将继续担任另一位联席公司秘书。追加内容 格隆汇12月12日丨昊海生物科技(06826.HK)公告，赵明璟已辞任(i)公司其中一位联席公司秘书；(ii)根 据香港联合交易所有限公司证券上市规则第3.05条所规定的公司授权代表；及(iii)根据上市规则第 19A.13(2)条及公司条例(香港法例第622章)第16部所规定的代公司于香港接受法律程序送达文件及通知 书的公司授权代表，自2025年12月12日起生效。 ...

Core Viewpoint - Haohai Biological Technology (06826.HK) announced a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, which will enhance its presence in the high-value medical device market for orthopedics and ophthalmology [1] Group 1 - The acquisition will be completed in three phases between 2025 and 2026, with total cash consideration of RMB 38,351,487.36 for Buyer I and RMB 4,755,979.05 for Buyer II [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury repair, and tear duct obstruction support [1] - By investing in the target company, the group aims to enter the high-value biological amniotic membrane market, complementing its existing product portfolio and expanding its business layout in orthopedics and ophthalmology [1] Group 2 - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in regenerative medicine and tissue engineering [1] - This investment is expected to drive subsequent product innovation and technological upgrades within the group [1]

Core Viewpoint - Haohai Biological Technology (688366) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.3515 million yuan, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Acquisition - The acquisition will be funded by the company's own capital [1] - The target company, Ruiji Biological, was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction procedures [1] - By investing in Ruiji Biological, the company aims to gain distribution rights for Ruiji's products in China, effectively entering the high-value medical device market of biological amniotic membranes [1] - This acquisition will enhance the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1]

格隆汇12月12日丨昊海生科(688366.SH)公布，为有效补充公司产品组合，增强业务抗风险能力及盈利 稳定性，并为公司创新材料产品开发奠定基础，经公司第六届董事会第六次会议审议通过，公司及独立 第三方钟晓燕与瑞济生物现有股东苗九昌、苗春云签订《股份转让框架协议》，分别以人民币3835.15 万元、475.6万元的价格分三个阶段受让苗九昌、苗春云合计持有的瑞济生物846.61万股、104.99万股股 份。交易完成后，公司将持有瑞济生物19.8000%的股份。本次交易资金来源为公司自有资金，不会导 致公司合并报表范围变更。 ...

格隆汇12月12日丨昊海生科(688366.SH)公布，为有效补充公司产品组合，增强业务抗风险能力及盈利 稳定性，并为公司创新材料产品开发奠定基础，经公司第六届董事会第六次会议审议通过，公司及独立 第三方钟晓燕与瑞济生物现有股东苗九昌、苗春云签订《股份转让框架协议》，分别以人民币3835.15 万元、475.6万元的价格分三个阶段受让苗九昌、苗春云合计持有的瑞济生物846.61万股、104.99万股股 份。交易完成后，公司将持有瑞济生物19.8000%的股份。本次交易资金来源为公司自有资金，不会导 致公司合并报表范围变更。 ...

Group 1 - The core point of the article is that Haohai Biological Technology (06826.HK) has entered into a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, with the total cash consideration amounting to RMB 38,351,487.36 for the first buyer and RMB 4,755,979.05 for the second buyer [1] Group 2 - The share transfer will be completed in three phases between 2025 and 2026 [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and lesion repair, and tear duct obstruction support [1] - By investing in the target company and obtaining distribution rights for its products in China, the group aims to enter the high-value medical device market of biological amniotic membranes, enhancing its existing product portfolio and expanding its business in orthopedics and ophthalmology [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive future product innovation and technological upgrades [1]

Core Viewpoint - Haohai Biological Technology (06826) announced plans to acquire approximately 19.8% and 2.4554% stakes in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for approximately 38.35 million yuan and 4.756 million yuan respectively, aiming to enter the high-value medical device market in China [1] Group 1 - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury lesion repair, and tear duct obstruction [1] - By investing in the target company and obtaining distribution rights for its products in China, the company aims to enhance its product portfolio and expand its business layout in the orthopedic and ophthalmic fields [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the company with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades [1]